Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients.
CONCLUSION: Retreatment with OXA in CRC patients is a feasible option even in patients who previously developed moderate or severe OIN. One-third of patients' OIN was worsened by retreatment. Neurological monitoring should be considered.
PMID: 29955956 [PubMed - indexed for MEDLINE]
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Besora S, Santos C, Izquierdo C, Martinez-Villacampa MM, Bruna J, Velasco R Tags: J Cancer Res Clin Oncol Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Neurology | Peripheral Neuropathy | Study | Toxicology